Aradigm Corporation and LungRx Inc. Agree to Develop AERx Essence(R) Technology for Use in Pulmonary Arterial Hypertension

Published: Sep 05, 2007

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) today announced it entered into an Exclusive License, Development and Commercialization Agreement (the “Agreement”) with Lung Rx, Inc., a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), for inhaled treprostinil using Aradigm’s AERx Essence® technology for the treatment of pulmonary arterial hypertension (PAH) and other potential therapeutic indications. AERx Essence inhalation delivery system is a palm-size, easy to use inhalation device that is expected to deliver medication to the patient in 2 to 4 breaths.

Back to news